All sickle cell community and investor eyes are on Mast Therapeutics (NYSEMKT:MSTX) this month, as MSTX prepares to roll out pivotal data from …
Healthcare analysts weighed in on development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and biopharmaceutical firm Mast Therapeutics (NYSEMKT:MSTX).
In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with a $3.00 …
